Program
larazotide acetate
Also written as “Larazotide Acetate”, “Larazotide” and “Larazotide acetate”.
Its studies are mostly in Celiac Disease · Fabry Disease, led by 3 companies.
Drug pageLarazotide acetate: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 9 Meters Biopharmaits history only | 80 open or running | phase 3since Jun 14, 2018 | Aug 8, 2006 | none ahead |
| BioMarin Pharmaceuticalits history only | 30 open or running | phase 1since Nov 10, 2011 | Nov 10, 2011 | none ahead |
| Interlude Biopharma | 11 open or running | phase 3since Nov 10, 2026 | Nov 10, 2026 | Aug 2028phase 3 · NCT07944625 |
Also a collaborator on its studies: Teva Pharmaceutical Industries.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Interlude Biopharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2026First study: phase 3 study in Celiac DiseaseFirst studyNCT07944625 · 414 planned
Ahead
- Aug 2028Primary completion: phase 3 study in Celiac DiseaseNCT07944625
TargetBeta
“Neuronal acetylcholine receptor; alpha3/beta4 partial agonist”ChEMBL 37, by rule
Studies
The one study Interlude Biopharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07944625Celiac Disease | 3 | Not yet recruiting | Aug 2028 | 414 |
How it is read
Names in the registry
- “larazotide acetate”, 5 entries
- “Larazotide Acetate”, 2 entries
- “Larazotide”, 1 entry
- “Larazotide acetate”, 1 entry
- “AT1001 150 mg”, 1 entry
Conditions, from the studies’ own filings
- Celiac Disease, 9 studies
- Fabry Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.